Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chia-Yu ChangYung-Hsin YehYi-Hsin ChanJia-Rou LiuShang-Hung ChangHsin-Fu LeeLung-Sheng WuKun-Chi YenChi-Tai KuoLai-Chu SeePublished in: Cardiovascular diabetology (2017)
Among patients with diabetes prescribed with metformin, the patients with DPP4i as second HA were associated with a lower risk of AF compared with the patients with other drugs as second HAs in real-world practice.
Keyphrases
- atrial fibrillation
- type diabetes
- oral anticoagulants
- catheter ablation
- left atrial
- primary care
- cardiovascular disease
- left atrial appendage
- glycemic control
- direct oral anticoagulants
- healthcare
- heart failure
- percutaneous coronary intervention
- quality improvement
- weight loss
- insulin resistance
- adipose tissue
- hyaluronic acid